SEC Questions COVID Drug Claims of Biotechs

The U.S. Securities and Exchange Fee has briefly halted buying and selling in the shares of three biotech organizations for the reason that of problems above the precision of statements they have produced about a drug candidate for treating COVID-19.

Houston-primarily based CNS Pharmaceuticals and WPD Pharmaceuticals of Vancouver, B.C., have stated they are creating a COVID-19 drug labeled WP1122, with Moleculin Biotech, also of Houston, as their license husband or wife.

The buying and selling suspensions are the SEC’s most up-to-date move “to crack down on untrue information concerning assessments, therapies or devices relating to the [coronavirus], which has contaminated far more than three.five million persons around the globe and killed far more than 248,000,” MarketWatch stated.

The fee has set short term halts on the shares of at least 29 organizations and past week sued Florida well being-treatment organization Praxsyn for fraud, alleging it produced “blatantly false” promises that it had secured a source of N95 masks.

According to the SEC, it suspended buying and selling in CNS, WPD, and Moleculin by way of May possibly 15 “because of queries concerning the precision and adequacy of information in the marketplace” about the organizations.

All those queries relate to statements produced by the companies in a collection of press releases considering that March 19 relating to the position of the growth and screening of WP1122 and their potential to expedite regulatory acceptance of the cure.

CNS shares have obtained about 28% in the previous thirty day period while Moleculin, thinly-traded nano cap, has obtained 88% and WPD has fallen 10%.

Moleculin announced on April eight that two-deoxy-D-glucose (two-DG) diminished the replication of the novel coronavirus by one hundred% in in vitro screening.

“Even however two-DG is lively in opposition to a selection of viruses, such as [the novel coronavirus], it isn’t valuable as a clinical therapy for the reason that it’s also promptly metabolized,” Moleculin Main Science Officer Don Picker stated in the launch. “WP1122 appears to remedy this difficulty for the reason that it is a ‘prodrug’ of two-DG’” that is metabolized to deliver two-DG.

Picker is also chief science officer of CNS and an advisor to WPD.

biotech, CNS Pharmaceuticals, coronavirus, COVID-19, Moleculin Biotech, U.S. Securities and Exchange Fee, WPD Pharmaceuticals